Abstract 1509P
Background
The lack of effective predictive biomarkers remains a major challenge in the management of patients (pt) with pancreatic ductal adenocarcinoma (PDAC). Tumor microenvironment and cytokines play an important role in the prognosis of pt with PDAC. Furthermore, the simultaneous analysis of molecular subtypes of PDAC may also allow the establishment of a correlation between certain cytokines and the molecular subtype.
Methods
This is a retrospective observational study. We included all pt with PDAC from whom a plasma sample had been collected before starting the first chemotherapy treatment at La Paz University Hospital between 2016 and 2022. We measured the plasma levels of the following cytokines by a bead-based fluorescence multiplex assay: TGF-β1-3, IL-1α, IL-1β, IL-6, IL-8, IL-9, IL-10, IP-10, IL-15, IL-17A and TNF-α. The expression of GATA6 and CK17 were tested by immunohistochemistry.
Results
A total of 73 pt were included. The increase in levels of IL-1α, IL-1β, IL-6, IL-8, IL-9, and IL-15 was associated with a higher risk of progression during first-line (1L). In addition, the increase in levels of these cytokines together with TGF-β1 and TNF-α was associated with a higher risk of mortality. Higher percentiles (p) of IL-1β, IL-6 were associated with shorter PFS during 1L and higher p of IL-6, IL-8, and TNF-α were correlated with shorter OS. Multivariate analysis showed that IL-8 levels were independently associated with increased risk of progression during 1L and with mortality (Table). Elevated levels of TGF-β2 were associated with basal-like and null subtypes (p=0.040) and increased levels of IL-17A were correlated with classical and mixed subtypes (p=0.021). In the multivariate analysis, TGF-β2 levels were independently associated with basal-like and null subtypes. Table: 1509P
Variables | p | HR | 95%CI |
Multivariate analysis for PFS during 1L | |||
IL-8 (reference group ConclusionsThe results of our study suggest that cytokines play a relevant role in the prognosis of patients with PDAC. Furthermore, their expression varies according to the molecular subtype. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest. Resources from the same session1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancerPresenter: Lai-Man Mok Session: Poster session 18 1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinomaPresenter: Minggui Pan Session: Poster session 18 1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-upPresenter: Marcia Cruz-Correa Session: Poster session 18 1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOWPresenter: Yoon-Koo Kang Session: Poster session 18 1439P - ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I studyPresenter: John Strickler Session: Poster session 18 1440P - Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trialPresenter: Chao Cheng Session: Poster session 18 1441P - Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancerPresenter: Weiyao Li Session: Poster session 18 1442P - Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudyPresenter: Hiroki Osumi Session: Poster session 18 1444P - Nature trumps nurture: Squamous cell carcinoma remains the leading cause of esophageal cancer in Asian-AmericansPresenter: Shubham Gulati Session: Poster session 18 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|